With a new $765,120 grant, Global Health professor Paul Drain will lead a study to develop an antigen-based COVID-19 test – as well as evaluate PCR-based tests and immunological assays – to be used at the point of care. This grant, sponsored by the Bill and Melinda Gates Foundation, is titled “Developing and Evaluating Point-of-Care Antigen and Immunoassays for COVID-19 and Cytokine Release Syndrome among people being screened for SARS-CoV-2 infection in Seattle”.
COVID-19 trials are short of enrollment - delaying much needed answers (Seattle Times, quotes Ruanne Barnabas and Christine Johnston)
One of the hottest debates in the coronavirus pandemic is whether the malaria drugs promoted as possible treatments by President Donald Trump really work. But Americans don’t seem overly eager to help answer the question.
Global Health Career Week, in collaboration with the School of Public Health, concluded with a Q&A panel on protecting public health during the COVID-19 pandemic. This live Zoom event provided participants with an opportunity to ask questions to our panel of experts.
Mask or No Mask? New Social Tension Splits Seattle-area Residents in Coronavirus Era (Seattle Times, quotes Jared Baeten)
You know the scene. You and a fellow shopper spot each other across the grocery store parking lot as you both head toward the building. One of you is wearing a mask. There’s an exchange of side-eye, judgmental glances between a person deemed too paranoid and a person deemed too cavalier.
3 Steps to Help Prevent Another Animal-to-Human Virus Pandemic (Seattle Times, co-written by Peter Rabinowitz)
By Peter Rabinowitz and Greg Gray
Governments and individuals are taking unprecedented, often very austere actions to control the ongoing spread of the pandemic coronavirus (SARS-CoV-2). However, they are neglecting an extremely important question that could cause the loss of millions of more lives — how do we prevent the next zoonotic respiratory virus pandemic?
We have not yet identified the source of this virus. What if a new version emerges from the original animal source to cause a second wave of this pandemic?
By Mariel Boyarsky (MPH, 2015)
Mariel Boyarsky graduated from the University of Washington in 2015 with a Master of Public Health in Global Health. After completing nursing school, she began working at Kings County Hospital in Brooklyn, New York in 2019. This is Mariel's firsthand account of working in the hospital during the COVID-19 pandemic.
Join us for this exciting new lecture series featuring UW researchers, covering topics from testing and response measures to vaccine development and social & economic impacts.
Are you a UW student interested in taking this course for credit? Please register for GH 590 B (SLN: 21809): Understanding the COVID-19 Pandemic.
Multisite Trial Early Data Suggests Remdesivir is Effective (UW Medicine Newsroom, Interview with Helen Chu)
Remdesivir, a non-specific antiviral drug that was originally tested against Ebola, has been shown to be effective against the new coronavirus in a preliminary data analysis, as reported by the National Institutes of Health. The UW School of Medicine was one of the sites in the National Institutes of Health trial. Dr.
Researchers have been studying COVID-19 in homeless communities, specifically in shelters with two or more confirmed cases in the weeks prior to their study. They found that in these shelters with clusters of cases, the proportion of positive tests was higher than in shelters with lower amounts of previously reported cases.
The University of Washington Population Health Initiative recently awarded 21 rapid response grants to study COVID-19. Four of these grants include faculty members from the Department of Global Health – Deepa Rao, Kristina Adams Waldorf, Bryan Weiner, and James Mullins.